Titan Pharmaceuticals, Inc. (NASDAQ:TTNP – Get Free Report) shares crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $5.12 and traded as low as $3.12. Titan Pharmaceuticals shares last traded at $3.61, with a volume of 47,798 shares.
Analyst Ratings Changes
Separately, StockNews.com began coverage on Titan Pharmaceuticals in a report on Friday. They set a “sell” rating on the stock.
Check Out Our Latest Analysis on Titan Pharmaceuticals
Titan Pharmaceuticals Stock Up 4.3 %
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Read More
- Five stocks we like better than Titan Pharmaceuticals
- What is Short Interest? How to Use It
- Top 3 Investment Themes to Watch for in 2025
- Industrial Products Stocks Investing
- Mega Buybacks in 2025: Why These 3 Leading Stocks Are Buys
- Consumer Staples Stocks, Explained
- AMD vs. NVIDIA: The Better Semiconductor Bet for 2025
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
